Pharmaceutical product list

Currently, the KD Pharma Group has 3 pharmaceutical drugs in the final stages of development in the US and EU. These new IP protected formulas address the cardiovascular and selected oncology sectors. The KD Pharma Group is also looking for Licensing Partners in various countries for these products. For more information please contact us at: pharma@kdpharmagroup.com

The KD Pharma Group is the only Omega-3 drug producer that has the full spectrum of separation technologies available on an industrial scale. These include distillation, HPE, SFE, SFC, Urea, Ag-extraction and others. This allows the KD Pharma Group to produce any fatty acid composition for the development and commercialization of new Omega-3 based pharmaceuticals. The majority of all new Omega-3 drug developments receive their API from the KD Pharma Group.

Active Pharmaceutical Ingredients (API)

• 465375EE (USP) bulk oil
   API for generic LOVAZA in the US and generic LOTRIGA in Japan

• 460380EE (EP) bulk oil
  API for generic OMACOR in EU and South Korea

• 550200FFA (USP) bulk oil
  API for generic EPANOVA in the US

Various: We can produce your specific Omega-3 API under full cGMP conditions.

KD Pharma's Approved Pharmaceutical Ingredients (APIs, mg/g)

KD-Pür® (mg/g) Pharmaceuticals